Consulting services for drug discovery in gene therapy
Official title: MEDICAL WRITING CONSULTING SERVICES
Funded at Ccs Associates, INC. · NIH-11199800 · Data updated 2026-11-12
This study is working with expert consultants to help create better gene therapies for very rare genetic conditions, so patients can eventually benefit from clearer communication and improved treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ccs Associates, INC. NIH-funded |
| Lab location | 1 site (San Jose, United States) |
| Project start | September 14, 2023 |
| Project end | September 13, 2025 |
| Funding year | 2024 |
| Award (this year) | $27,295 |
| NIH project number | 75N95023P00692-P00001-0-2 |
| Project ID | NIH-11199800 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with ultra-rare genetic disorders who may benefit from advanced gene therapies.
✕Less likely to help
Patients with common genetic disorders or those not involved in gene therapy may not receive direct benefits from this research.
What this research studies
This research involves hiring experienced consultants to provide guidance and leadership in the development of drug therapies targeting ultra-rare genetic conditions. The consultants will focus on medical writing and documentation to support drug discovery and development projects. Patients may benefit from improved communication and documentation practices that enhance the quality of gene therapy programs. The approach aims to streamline the process of bringing innovative gene-based therapies to clinical use.
Why it matters
Potential benefit: If successful, this research could lead to more effective and well-documented gene therapies for patients with ultra-rare genetic conditions.
How similar studies have gone: While this approach focuses on consulting and documentation, similar initiatives in drug development have shown success in improving the efficiency and effectiveness of bringing new therapies to market.
Where this research is happening
-
Ccs Associates, INC.
San Jose, United States Active
Researchers
- Principal investigator: Sigman, Caroline C — Ccs Associates, INC.
- Study coordinator: Sigman, Caroline C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.